In addition, the synergistic pathogenic effects of DNMT3A and coexisting mutations need to explore their molecular mechanisms to provide directions for delineating AML subgroups and refining therapeutic strategies. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.